Meta's Muse Could Generate $27 Billion a Year, Citi Says as AI Agent Usage Surges
Citi says Meta’s fast-growing Muse AI agent could generate more than $27 billion in annual revenue by 2030.
Stocks · News reference
Weight Watchers Expands GLP-1 Era Strategy With Google Health
Weight Watchers partners with Google Health to integrate Fitbit data and AI insights into select employer programs. WW stock surges 12%.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Broadcom's AI Revenue Is Growing at 221%. Here's Why Custom Chips Could Be a Bigger Business Than GPUs.
Broadcom's AI semiconductor revenue surged 221% year-over-year in Q3, driven by custom AI accelerators (XPUs) designed with hyperscalers like Google, Meta, and OpenAI. Custom chips offer better power efficiency, faster inference, and higher returns on capital compared to GPUs, making them increasingly attractive as hyperscalers face capital constraints. While Nvidia's data center business is currently 4x larger, custom silicon is winning by volume among major customers and could eventually become a bigger business than GPUs.
Google, Unity Collaborate For New, Integrated Gaming Platform To Be Launched Later In 2026
Google and Unity today announced a strategic partnership for a new, integrated gaming platform coming later this year designed to revolutionize the next era of gaming. Bringing together the power of Google AI, the reach
Should You Buy SpaceX Stock in October?
SpaceX has expanded significantly beyond rockets into AI infrastructure, with major compute contracts worth billions annually from companies like Reflection AI, Google, and Anthropic. Recent milestones include Starship reaching orbit and successful launch cadences. However, at a $2 trillion valuation, the stock may already reflect this growth. The author recommends dollar-cost averaging rather than chasing momentum ahead of Q3 earnings, as the company needs to demonstrate these contracts are translating into actual revenue and improved economics.
Cathie Wood's $22M Biotech Shuffle, Dumps One Stock for 21st Straight Session While Other Bets Pile Up
Cathie Wood's ARK dumps $18M of Twist Bioscience while buying Recursion, Veracyte and Intellia, extending its CRISPR bet to 50 sessions.
Eli Lilly and vs. Novo Nordisk A/S: Which Healthcare Stock Is a Better Buy in 2026?
Eli Lilly and Novo Nordisk compete in the booming GLP-1 weight-loss and diabetes treatment market. Eli Lilly demonstrates superior growth with 44.7% revenue increase and 49.7% operating margins, while Novo Nordisk offers better valuation (3x lower P/E ratio) and higher dividend yield (4.8% vs 0.6%). The author favors Eli Lilly for growth-oriented investors despite its premium valuation.